Cetuximab
- Generic Name
- Cetuximab
- Brand Names
- Erbitux
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 205923-56-4
- Unique Ingredient Identifier
- PQX0D8J21J
- Background
Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelia...
- Indication
Cetuximab indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. It is indicated for treating a recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. It is indicated for r...
- Associated Conditions
- Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Metastatic Colorectal Cancer (CRC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Regionally Advanced Squamous Cell Carcinoma of the Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Associated Therapies
- -
Radiation Plus Cetuximab in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- First Posted Date
- 2005-06-23
- Last Posted Date
- 2011-08-05
- Lead Sponsor
- Heidelberg University
- Target Recruit Count
- 30
- Registration Number
- NCT00115518
- Locations
- 🇩🇪
University of Heidelberg, Heidelberg, Germany
Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-06-02
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 755
- Registration Number
- NCT00112294
- Locations
- 🇺🇸
Local Institution, Madison, Wisconsin, United States
S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2012-11-01
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 242
- Registration Number
- NCT00085501
- Locations
- 🇺🇸
Sletten Regional Cancer Institute, Great Falls, Montana, United States
🇺🇸Gibbs Regional Cancer Center at Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States
🇺🇸CCOP - Atlanta Regional, Atlanta, Georgia, United States
FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum
- Conditions
- Interventions
- First Posted Date
- 2004-02-11
- Last Posted Date
- 2018-05-16
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 238
- Registration Number
- NCT00077233
- Locations
- 🇺🇸
Memorial Regional Cancer Center at Memorial Regional Hospital, Hollywood, Florida, United States
🇺🇸MBCCOP - University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States
Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer
- First Posted Date
- 2003-06-25
- Last Posted Date
- 2010-04-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1302
- Registration Number
- NCT00063141
- Locations
- 🇬🇧
ImClone Investigational Site, Sutton, Surrey, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.